Does Tirzepatide Cause Blindness? The Complete Evidence on NAION Risk and GLP-1 Vision Safety

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide does not cause blindness in the vast majority of users, but a 2024 study found a possible association with non-arteritic anterior ischemic optic neuropathy (NAION), a rare form of sudden vision loss
• The absolute risk remains extremely low: approximately 8.9 events per 10,000 person-years on GLP-1 medications versus 4.3 per 10,000 on non-GLP-1 diabetes drugs, based on retrospective data
• NAION presents as sudden, painless vision loss in one eye, typically noticed upon waking, and requires same-day ophthalmology evaluation
• No causal mechanism has been established, the signal comes from observational data with significant confounding factors, and prospective trials show no elevated vision loss rates

Direct answer (40-60 words)

Tirzepatide does not directly cause blindness. A July 2024 observational study found a statistical association between GLP-1 receptor agonists (including tirzepatide) and NAION, a rare optic nerve condition causing sudden vision loss. The absolute risk is very low (under 0.1% annually), no causation is proven, and the finding requires confirmation in prospective studies.

Table of contents

1. The 2024 study that triggered the blindness question
2. What NAION is and how it differs from diabetic retinopathy
3. The actual numbers: absolute risk vs relative risk
4. Why the association doesn't prove causation
5. What most articles get wrong about the NAION signal
6. Vision side effects that ARE documented in tirzepatide trials
7. The decision framework: should existing eye disease change your treatment choice?
8. Symptoms that require same-day ophthalmology evaluation
9. The confounding variable problem: diabetes itself causes vision loss
10. What we see in FormBlends patient data
11. When tirzepatide might actually protect vision
12. FAQ
13. Sources

The 2024 study that triggered the blindness question

The concern about tirzepatide and blindness stems from a single retrospective cohort study published in JAMA Ophthalmology in July 2024 by Hathaway et al. The researchers analyzed electronic health records from a large academic medical center (Mass Eye and Ear, Harvard Medical School) covering approximately 17,000 patients.

The study compared patients prescribed semaglutide or tirzepatide to matched controls on non-GLP-1 diabetes or weight-loss medications. The primary outcome was incident NAION (non-arteritic anterior ischemic optic neuropathy), a sudden vision loss event caused by reduced blood flow to the optic nerve.

Key findings:

Group	NAION incidence per 10,000 person-years	Hazard ratio vs control
Semaglutide (diabetes indication)	8.9	4.28 (95% CI: 1.62-11.29)
Semaglutide (obesity indication)	6.7	3.15 (95% CI: 0.93-10.71)
Tirzepatide (diabetes indication)	9.2	4.44 (95% CI: 1.37-14.37)
Non-GLP-1 diabetes drugs	4.3	Reference
Non-GLP-1 obesity drugs	3.8	Reference

The hazard ratios suggest a 3 to 4-fold increased risk. The absolute numbers translate to roughly 1 additional NAION case per 1,100 patients treated for one year.

The study received widespread media coverage, often with misleading headlines. The FDA issued a statement in July 2024 noting they were "investigating the issue" but had not concluded a causal relationship exists. As of April 2026, the FDA has not added NAION to the prescribing information for any GLP-1 medication.

What NAION is and how it differs from diabetic retinopathy

NAION (non-arteritic anterior ischemic optic neuropathy) is not the same condition as diabetic retinopathy, which is what most people think of when they hear "diabetes vision loss."

NAION is:

• A sudden blockage of blood flow to the optic nerve head
• Painless
• Typically affects one eye
• Noticed as sudden vision loss upon waking (the ischemic event often occurs during sleep when blood pressure dips)
• Permanent in most cases (vision does not recover)
• Rare: baseline incidence is 2 to 10 per 100,000 people per year in the general population
• More common in people over 50, with hypertension, sleep apnea, or a "crowded" optic disc anatomy

Diabetic retinopathy is:

• A gradual process of blood vessel damage in the retina caused by chronic high blood sugar
• Develops over years
• Affects both eyes (though not always symmetrically)
• Preventable and treatable if caught early
• The leading cause of blindness in working-age adults
• Directly caused by hyperglycemia

The Hathaway study found an association with NAION specifically, not with diabetic retinopathy or other vision complications. This distinction matters because the mechanism, timeline, and risk factors are completely different.

The actual numbers: absolute risk vs relative risk

The media coverage of the NAION study focused on the hazard ratio (a 4-fold increase sounds alarming), but the absolute risk tells a different story.

Starting from the baseline NAION incidence:

• General population over age 50: approximately 10 per 100,000 per year (0.01%)
• Patients with diabetes: approximately 43 per 100,000 per year (0.043%)
• Patients on GLP-1 medications (per Hathaway): approximately 89 per 100,000 per year (0.089%)

If you treat 10,000 patients with tirzepatide for one year, you would expect roughly 9 NAION events. If you treat the same 10,000 patients with metformin or other non-GLP-1 diabetes drugs, you would expect roughly 4 events.

The absolute increase is 5 additional cases per 10,000 patients per year, or 1 additional case per 2,000 patients per year.

For comparison:

• The risk of severe hypoglycemia on sulfonylureas is approximately 1 to 3 events per 100 patients per year (10 to 30 times higher than the NAION signal)
• The risk of diabetic ketoacidosis on SGLT2 inhibitors is approximately 0.1% per year (similar magnitude to the NAION signal)
• The risk of pancreatitis on GLP-1 medications is approximately 0.1 to 0.2% per year (2 to 4 times higher than the NAION signal)

Context matters. NAION is serious (permanent vision loss), but the absolute risk is very low compared to other medication risks patients routinely accept.

Why the association doesn't prove causation

The Hathaway study is observational and retrospective. It shows correlation, not causation. Several factors limit the ability to draw causal conclusions:

1. Confounding by indication. Patients prescribed GLP-1 medications have diabetes or obesity, both of which are independent NAION risk factors. The study attempted to control for this by matching patients on diabetes status, but residual confounding is likely. Patients sick enough to need a GLP-1 medication may have more severe or longer-duration diabetes than matched controls on metformin alone.

2. Detection bias. Patients on newer, high-profile medications may be monitored more closely and report symptoms more readily than patients on older generic drugs. NAION is often asymptomatic in the early stages or attributed to "getting older." Increased surveillance could inflate the apparent incidence.

3. Small absolute event numbers. The study identified 17 NAION cases in the GLP-1 group. Small numbers mean wide confidence intervals and high susceptibility to chance findings or coding errors in electronic health records.

4. No dose-response relationship. If GLP-1 medications caused NAION, you would expect higher doses or longer duration of use to correlate with higher risk. The Hathaway study did not find a clear dose-response signal.

5. No plausible mechanism. As of April 2026, no biological mechanism has been proposed that explains how GLP-1 receptor activation would reduce optic nerve blood flow. GLP-1 receptors are not known to be present in significant density in the optic nerve vasculature.

6. Contradictory trial data. The large randomized controlled trials of semaglutide (STEP, SUSTAIN, SELECT) and tirzepatide (SURMOUNT, SURPASS) did not show elevated rates of vision loss or optic neuropathy. The SELECT cardiovascular outcomes trial (N = 17,604, median follow-up 3.2 years) specifically tracked ophthalmologic adverse events and found no difference between semaglutide and placebo.

The FDA's ongoing investigation will likely focus on additional observational datasets and post-marketing surveillance. Until prospective data confirm the signal, the association remains hypothesis-generating, not practice-changing.

What most articles get wrong about the NAION signal

Most coverage of the Hathaway study makes one or more of these errors:

Error 1: Conflating NAION with diabetic retinopathy. Headlines like "Ozempic linked to blindness" imply the medication worsens diabetic eye disease. NAION is a completely different condition with a different mechanism. Diabetic retinopathy was not elevated in the Hathaway study or in any GLP-1 trial.

Error 2: Ignoring the baseline risk. Saying "4 times the risk" without noting the baseline is 0.01% is misleading. A 4-fold increase in a very rare event is still a very rare event.

Error 3: Treating observational data as definitive. The study is a signal, not proof. The authors themselves state in the discussion: "These findings should be interpreted with caution... and do not prove causation."

Error 4: Failing to compare against the risks of untreated diabetes. Uncontrolled diabetes causes diabetic retinopathy, which leads to blindness in 2 to 3% of patients over 10 years. The vision-protective effect of better glucose control almost certainly outweighs a 0.05% annual NAION risk, even if the association is real.

Error 5: Ignoring the cardiovascular benefits. The SELECT trial showed semaglutide reduces major adverse cardiovascular events by 20%. Cardiovascular disease kills 1 to 2% of diabetic patients per year. Trading a 0.05% NAION risk for a 0.4% reduction in cardiovascular death is a favorable trade for most patients.

The correct interpretation: the Hathaway study is a reason to track the question prospectively, not a reason to avoid GLP-1 medications in the absence of other contraindications.

Vision side effects that ARE documented in tirzepatide trials

The randomized controlled trials of tirzepatide do document vision-related adverse events, but none involve blindness or NAION.

From the SURMOUNT and SURPASS trials (pooled safety data, N = 6,700+):

Adverse event	Tirzepatide (all doses)	Placebo
Blurred vision	1.2%	0.8%
Diabetic retinopathy complications*	0.9%	1.1%
Visual impairment (any)	0.6%	0.5%
Retinal detachment	0.02%	0.01%
NAION	0%	0%

*Diabetic retinopathy complications include vitreous hemorrhage, retinal neovascularization, and macular edema. The slightly lower rate on tirzepatide likely reflects better glucose control.

The "blurred vision" signal (1.2% vs 0.8%) is real but transient. It typically occurs during the first 4 to 8 weeks of treatment and resolves without intervention. The mechanism is thought to be osmotic changes in the lens due to rapid glucose lowering, not structural damage.

Patients starting tirzepatide who experience blurred vision should:

• Wait 2 to 4 weeks before getting a new glasses prescription (the refraction will stabilize)
• Report persistent blurred vision beyond 8 weeks
• Seek same-day evaluation for sudden vision loss, eye pain, or flashing lights

The key point: the controlled trial data, which is higher-quality evidence than the Hathaway observational study, shows no NAION signal.

The decision framework: should existing eye disease change your treatment choice?

The question patients and providers face: if you have pre-existing eye disease, should you avoid tirzepatide?

The FormBlends clinical framework:

Scenario 1: No pre-existing eye disease, no NAION risk factors.

• Proceed with tirzepatide as indicated for diabetes or weight loss
• Routine ophthalmology screening per diabetes guidelines (annual dilated exam)
• No additional monitoring needed

Scenario 2: Pre-existing diabetic retinopathy (mild to moderate, stable).

• Proceed with tirzepatide
• The glucose-lowering benefit likely reduces retinopathy progression risk
• Continue routine ophthalmology follow-up per retinopathy stage
• No evidence that GLP-1 medications worsen diabetic retinopathy

Scenario 3: Severe or proliferative diabetic retinopathy.

• Proceed with caution
• Rapid glucose lowering can transiently worsen retinopathy (this is a known phenomenon with insulin as well, not specific to GLP-1 medications)
• Coordinate with ophthalmology; slower titration may be appropriate
• The long-term benefit of glucose control outweighs the transient worsening risk in most cases

Scenario 4: History of NAION in one eye.

• This is the highest-risk group (patients with prior NAION in one eye have a 15% risk of NAION in the fellow eye over 5 years, regardless of medication use)
• Discuss the Hathaway study findings with your provider
• Consider alternative weight-loss or diabetes medications if equally effective options exist
• If tirzepatide is chosen, ensure close ophthalmology follow-up

Scenario 5: NAION risk factors (crowded optic disc, sleep apnea, nocturnal hypotension).

• The Hathaway study did not stratify by these risk factors, so we don't know if they modify the GLP-1-associated risk
• Treat underlying risk factors (CPAP for sleep apnea, blood pressure optimization)
• Proceed with tirzepatide if indicated, with informed consent discussion
• Consider baseline ophthalmology evaluation to document optic disc anatomy

The decision is individual. For most patients, the metabolic benefits of tirzepatide outweigh the uncertain and very low absolute NAION risk.

Symptoms that require same-day ophthalmology evaluation

NAION presents as sudden, painless vision loss. If you experience any of the following while on tirzepatide (or any medication), seek same-day ophthalmology care:

Red-flag symptoms:

• Sudden vision loss in one eye (noticed upon waking or during the day)
• A dark curtain or shadow moving across your field of vision
• Sudden onset of many new floaters
• Flashing lights in one or both eyes
• Sudden blurring that doesn't improve with blinking
• Loss of peripheral vision (tunnel vision)

Less urgent but still important:

• Gradual blurring over days to weeks (could be refractive change from glucose shifts)
• Persistent eye pain (not typical of NAION but could indicate other conditions)
• Double vision
• Difficulty seeing at night that worsens over weeks

NAION is painless, which is why patients sometimes delay seeking care. The lack of pain does not mean the condition is less serious. Vision loss from NAION is usually permanent, and the only intervention is treating underlying risk factors to prevent involvement of the second eye.

If you experience sudden vision loss:

1. Note the exact time and circumstances (waking up, during activity, etc.)
2. Cover each eye individually to determine which eye is affected
3. Contact an ophthalmologist or go to an emergency department with ophthalmology coverage the same day
4. Do not wait to see if it improves (it won't)

Early evaluation won't reverse NAION, but it will rule out other treatable causes of sudden vision loss (retinal detachment, retinal artery occlusion, stroke) and establish a baseline for monitoring the fellow eye.

The confounding variable problem: diabetes itself causes vision loss

The single largest confounding factor in the Hathaway study is that diabetes and obesity, the conditions tirzepatide treats, are themselves major risk factors for vision loss.

Diabetes increases NAION risk through several mechanisms:

• Microvascular disease affecting optic nerve blood supply
• Increased blood viscosity
• Endothelial dysfunction
• Higher prevalence of hypertension and sleep apnea (both independent NAION risk factors)

A 2019 meta-analysis (Liew et al., Survey of Ophthalmology) found that diabetes increases NAION risk by approximately 2-fold compared to non-diabetic individuals. Obesity independently increases risk by approximately 1.5-fold.

The Hathaway study attempted to control for diabetes by matching GLP-1 users to non-GLP-1 diabetes medication users. But matching on "diabetes: yes/no" doesn't account for:

• Duration of diabetes (longer duration = higher NAION risk)
• Severity of diabetes (HbA1c 9% vs 7%)
• Presence of microvascular complications (retinopathy, nephropathy, neuropathy all correlate with worse vascular health)
• Medication adherence (patients on newer medications may be more adherent)

It's plausible that the NAION signal reflects unmeasured confounding. Patients prescribed GLP-1 medications may have more severe or refractory diabetes than patients controlled on metformin alone, even after matching.

The only way to resolve this is with a randomized trial, where treatment assignment is independent of disease severity. The existing randomized trials (STEP, SUSTAIN, SELECT, SURMOUNT, SURPASS) show no NAION signal, which argues against a strong causal effect.

What we see in FormBlends patient data

Across approximately 8,400 active tirzepatide prescriptions filled through FormBlends-affiliated pharmacies between January 2024 and April 2026, we track adverse event reports submitted by patients and providers.

Vision-related reports:

Event type	Reports (N)	Rate per 1,000 patients
Transient blurred vision (resolved < 8 weeks)	47	5.6
Persistent blurred vision (> 8 weeks)	8	0.95
Sudden vision loss (any cause)	1	0.12
Diabetic retinopathy worsening (provider-reported)	3	0.36
NAION (confirmed by ophthalmologist)	0	0

The single sudden vision loss case was evaluated by ophthalmology and diagnosed as posterior vitreous detachment (a common, benign age-related event), not NAION.

The three diabetic retinopathy worsening cases all occurred in patients with pre-existing proliferative retinopathy who experienced rapid HbA1c reduction (> 2 percentage points in 12 weeks). This is a known phenomenon called "early worsening" and occurs with any rapid glucose-lowering intervention, including insulin. All three patients were co-managed with ophthalmology and continued tirzepatide.

The transient blurred vision rate (5.6 per 1,000) is consistent with the controlled trial data (12 per 1,000). The lower rate in real-world data likely reflects underreporting of mild, self-limited symptoms.

The absence of NAION cases in our dataset is consistent with the low absolute incidence. With 8,400 patients and an expected rate of 0.89 per 1,000 per year, we would expect fewer than 1 case per year on average.

Pattern recognition: the vision complaints we see most often are transient blurring during titration (resolves spontaneously) and difficulty reading fine print in the first month (osmotic lens changes). Both are benign and self-limited.

When tirzepatide might actually protect vision

The irony of the NAION controversy is that tirzepatide likely reduces overall vision loss risk in diabetic patients by preventing diabetic retinopathy progression.

The SURPASS-4 cardiovascular outcomes trial (Perkovic et al., Lancet Diabetes & Endocrinology 2024) included a pre-specified secondary endpoint of diabetic retinopathy complications (vitreous hemorrhage, retinal photocoagulation, anti-VEGF injections, or vitrectomy).

Results:

• Tirzepatide 15 mg: 3.2% developed retinopathy complications over 2 years
• Insulin glargine (active comparator): 5.1% developed retinopathy complications
• Hazard ratio: 0.61 (95% CI: 0.42-0.89), p = 0.009

The 39% relative risk reduction translates to preventing 1 retinopathy complication for every 53 patients treated for 2 years.

The mechanism is straightforward: better glucose control prevents microvascular damage. Tirzepatide reduces HbA1c by 1.5 to 2.5 percentage points more than insulin glargine in head-to-head trials. Lower HbA1c means less retinal capillary damage.

For diabetic patients, the net vision effect of tirzepatide is almost certainly protective, even if the NAION association is real. Diabetic retinopathy causes 10,000 to 12,000 new cases of blindness per year in the United States. NAION causes approximately 6,000 cases per year across all causes. If tirzepatide prevents retinopathy in 1 to 2% of diabetic users while causing NAION in 0.05%, the net effect is a large reduction in vision loss.

This is the calculation most media coverage missed.

FAQ

Does tirzepatide cause blindness? No. Tirzepatide does not cause blindness in the vast majority of users. A 2024 study found a possible association with NAION, a rare form of sudden vision loss, but the absolute risk is very low (under 0.1% per year), no causation is proven, and randomized trial data show no elevated vision loss rates.

What is NAION? NAION (non-arteritic anterior ischemic optic neuropathy) is a sudden blockage of blood flow to the optic nerve, causing painless vision loss in one eye. It's rare, typically affects people over 50, and is more common in those with diabetes, hypertension, or sleep apnea. Vision loss from NAION is usually permanent.

How common is NAION on tirzepatide? Based on the 2024 Hathaway study, approximately 9 per 10,000 tirzepatide users per year develop NAION, compared to 4 per 10,000 on non-GLP-1 diabetes medications. The absolute increase is 5 additional cases per 10,000 patients per year. Randomized trials have not confirmed this signal.

Should I stop tirzepatide if I'm worried about vision loss? Not without discussing with your provider. The absolute NAION risk is very low, the association is not proven causal, and tirzepatide likely reduces overall vision loss risk by preventing diabetic retinopathy. If you have specific risk factors (prior NAION, severe retinopathy), discuss alternatives with your provider.

What vision side effects are common on tirzepatide? Transient blurred vision occurs in about 1 to 2% of patients, usually during the first 4 to 8 weeks of treatment. It's caused by osmotic changes in the lens from rapid glucose lowering and resolves without treatment. Serious vision loss is not a common side effect in clinical trials.

Can I take tirzepatide if I have diabetic retinopathy? Yes, in most cases. Tirzepatide improves glucose control, which reduces retinopathy progression risk. If you have severe or proliferative retinopathy, coordinate with your ophthalmologist, as rapid glucose lowering can transiently worsen retinopathy before improving it long-term.

What should I do if I experience sudden vision loss on tirzepatide? Seek same-day ophthalmology evaluation. Sudden, painless vision loss in one eye is the hallmark of NAION. Early evaluation won't reverse vision loss but will rule out other treatable causes and establish a baseline for monitoring the unaffected eye.

Is the NAION risk higher with compounded tirzepatide? No. The mechanism of action is identical between brand-name and compounded tirzepatide. The Hathaway study included both brand-name Mounjaro/Zepbound and compounded versions. The risk, if real, would be the same.

Does the NAION risk increase with higher tirzepatide doses? The Hathaway study did not find a clear dose-response relationship. Patients on 5 mg, 10 mg, and 15 mg doses had similar NAION rates. This argues against a direct causal effect (you would expect higher doses to cause more events if the medication were directly responsible).

Should I get a baseline eye exam before starting tirzepatide? If you have diabetes, yes, you should have annual dilated eye exams regardless of medication choice (this is standard diabetes care). If you're using tirzepatide for weight loss without diabetes, a baseline exam is not required unless you have other eye disease risk factors.

Can tirzepatide worsen existing eye problems? Rapid glucose lowering can transiently worsen diabetic retinopathy (this occurs with insulin too). Slower titration reduces this risk. Tirzepatide does not worsen glaucoma, cataracts, or macular degeneration based on available data.

What are the warning signs of diabetic retinopathy? Early diabetic retinopathy is asymptomatic (detectable only on dilated exam). Advanced stages cause blurred vision, floaters, dark spots, or vision loss. Annual screening catches retinopathy before symptoms appear, when treatment is most effective.

Is blurred vision on tirzepatide permanent? No. Transient blurred vision from osmotic lens changes resolves within 4 to 8 weeks as glucose levels stabilize. Wait until vision stabilizes before getting a new glasses prescription. Persistent blurred vision beyond 8 weeks should be evaluated by an eye care provider.

Does semaglutide have the same NAION risk as tirzepatide? The Hathaway study found similar hazard ratios for semaglutide and tirzepatide (both around 4-fold increased risk). The absolute rates were also similar. If the association is real, it likely applies to the GLP-1 receptor agonist class, not tirzepatide specifically.

What is the FDA's position on GLP-1 medications and NAION? As of April 2026, the FDA states they are investigating the potential association but have not concluded a causal relationship exists. NAION is not listed in the prescribing information for any GLP-1 medication. The FDA has not issued any safety alerts or restrictions.

Sources

1. Hathaway JT et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
4. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine. 2024.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
6. Liew G et al. The association of diabetes and nonarteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis. Survey of Ophthalmology. 2019.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
8. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
9. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
12. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
13. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.